Gene Universal

Executive Summary

Gene Universal is a US-based contract research organization (CRO) founded in 2020 that provides molecular biology services including gene synthesis, protein and antibody expression, viral vector packaging, and custom assay development. Serving academic, biopharma, and diagnostic clients, the company aims to accelerate R&D programs through comprehensive, customizable offerings. As a private entity with no disclosed funding or revenue, Gene Universal operates in a competitive CRO landscape but may differentiate through its integrated service suite. The company is positioned to capitalize on growing demand for outsourced biotech services, particularly in gene therapy and diagnostics, though its early stage and lack of public milestones present uncertainty. Conviction is moderate given the fragmented market and need for continued client acquisition and service expansion.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement40% success
• Q2 2027Strategic Partnership with a Mid-Size Pharma35% success
• Q3 2026Launch of New Service Line (e.g., CRISPR-based assays)50% success